{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:55:30Z","timestamp":1789016130670,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF16OC0019302"],"award-info":[{"award-number":["NNF16OC0019302"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of new malignancies. However, limited data have been published about the impact of CLL treatment on this risk. Here we followed a Danish population\u2010based cohort of CLL patients for risks of new malignancies. Patients in the Danish CLL registry (2008\u20132017) were included. Up to 50 CLL\u2010free matched comparators were identified. First\u2010line treatment was categorized into four groups; bendamustine, chlorambucil, fludarabine or other. Patients were followed from CLL diagnosis for individual types of malignancy. Adjusted hazard ratios (HR) for new malignancies and 95% confidence intervals (95% CI) were calculated. Overall, 4286 CLL patients and 214\u00a0150 controls developed 594 and 20\u00a0565 new malignancies respectively. Risk of new malignancies was increased for CLL patients. Chemotherapy treatment was registered for 1064 (25%) patients with CLL. Chemotherapy was associated with increased HR (1\u00b751, 95% CI: 1\u00b73\u20131\u00b78) of any new malignancy. Specifically, fludarabine was associated with an increased risk of myelodysplastic syndrome (MDS) (HR 4\u00b793, 95% CI: 1\u00b72\u201319\u00b78). Patients with CLL are at increased risk of other haematological and solid malignancies compared to the general population. Chemotherapy exposure is associated with increased risk of second malignancies and fludarabine is associated with increased risk of MDS.<\/jats:p>","DOI":"10.1111\/bjh.17337","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T21:42:16Z","timestamp":1613252536000},"page":"339-345","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population\u2010based study"],"prefix":"10.1111","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-3098","authenticated-orcid":false,"given":"Caspar","family":"da Cunha\u2010Bang","sequence":"first","affiliation":[{"name":"Department of Hematology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Rostgaard","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Research Statens Serum Institut \u2013 SSI Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark"},{"name":"Department of Epidemiology Research Statens Serum Institut \u2013 SSI Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie C.","family":"Rotbain","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark"},{"name":"Department of Hematology Odense University Hospital Odense Denmark"},{"name":"Department of Clinical Research University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen Copenhagen Denmark"},{"name":"Biotech Research &amp; Innovation Centre (BRIC) University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Frederiksen","sequence":"additional","affiliation":[{"name":"Department of Hematology Odense University Hospital Odense Denmark"},{"name":"Department of Clinical Research University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjalgrim","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark"},{"name":"Department of Epidemiology Research Statens Serum Institut \u2013 SSI Copenhagen Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22672"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5398"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050156"},{"issue":"8","key":"e_1_2_8_5_1","first-page":"1","article-title":"Bendamustine: mechanism of action and clinical data","volume":"9","author":"Cheson BD","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241020-00002"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S99486"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810393562"},{"issue":"2","key":"e_1_2_8_10_1","first-page":"337","article-title":"Subsequent cancer in patients with chronic lymphocytic leukemia\u2010a possible immunologic mechanism","volume":"61","author":"Greene MH","year":"1978","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.642"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800570"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1720::AID-CNCR13>3.0.CO;2-X"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.381"},{"issue":"1","key":"e_1_2_8_15_1","first-page":"27","article-title":"Impairments in immune cell function in B cell chronic lymphocytic leukemia","volume":"25","author":"Bartik MM","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01044"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.957203"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003539"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0237-1"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.218"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0987-6"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13146"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220194"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T04:11:58Z","timestamp":1693541518000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/bjh.17337"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17337","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]},"assertion":[{"value":"2020-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}